This site is intended for health professionals only

Wednesday 19 June 2019
Share |

Latest News

Lynparza approved for first-line maintenance treatment of BRCA-mutated advanced ovarian cancer

Tuesday 18th June 2019
AstraZeneca and MSD have announced that the European Commission (EC) has approved Lynparza (olaparib) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer.
The licensed indication is as a maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (...
Thu, 6 Jun 2019
Psychiatric comorbidities, including intellectual disability and depression, are common for adults who have epilepsy
Thu, 6 Jun 2019
The risk of pneumonia was highest among those using strong opioids, such as oxycodone or fentanyl, but the risk was also increased among those using buprenorphine, tramadol or codeine
Thu, 6 Jun 2019
The results support a robust set of existing data demonstrating the sustained efficacy, safety, and tolerability of continuous ibrutinib treatment in patients with CLL
Thu, 6 Jun 2019
In the Phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps with inadequate response to intranasal corticosteroids
Sun, 2 Jun 2019
The evidence-based recommendations for the prevention and management of adult antiphospholipid syndrome are designed to help guide practice – and improve quality of care and patient outcomes
Fri, 31 May 2019
A Federation called Sjögren Europe has been created by the national patient associations of ten European countries
Thu, 30 May 2019
QUARTZ is the first completed study of the Phase III PLATINUM clinical development program which evaluates both QMF149 and QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate)